Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE versus DEXONE 0 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE versus DEXONE 0 5.
DEXAMETHASONE vs DEXONE 0.5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, leading to altered gene expression and suppression of inflammatory mediators.
Dexamethasone is a glucocorticoid receptor agonist, binding to the glucocorticoid receptor (GR) and modulating gene expression through transactivation and transrepression. It inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, suppresses cytokine production (IL-1, IL-2, IL-6, TNF-alpha), and decreases immune cell migration and activation.
0.5-24 mg/day oral, IV, IM in 2-4 divided doses; anti-inflammatory: 0.75-9 mg/day; multiple myeloma: 40 mg oral/IV once daily on days 1-4, 9-12, 17-20 every 28 days.
0.5 mg orally once daily, with gradual taper to lowest effective dose
None Documented
None Documented
Clinical Note
moderateDexamethasone + Digoxin
"Dexamethasone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDexamethasone + Digitoxin
"Dexamethasone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDexamethasone + Deslanoside
"Dexamethasone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDexamethasone + Acetyldigitoxin
"Dexamethasone may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life 3-4 hours; clinically, duration of HPA suppression may exceed 24 hours due to prolonged receptor binding.
3.0-4.5 hours; prolonged in hepatic impairment (up to 6-8 hours) or concurrent CYP3A4 inhibitors
Primarily renal (65-80% as unchanged drug); minor biliary/fecal (<10%).
Renal: 70-80% (mostly as 6β-hydroxydexamethasone); biliary/fecal: 10-15%
Category D/X
Category C
Corticosteroid
Corticosteroid